The following table presents share-based compensation cost and the unrecognized compensation cost by award type (in millions):


	Amount of share-based compensation cost recognized						Unrecognized compensation cost		Weighted-average remaining term (in years)
	Year ended December 31,						December 31,
	2025		2024		2023		2025
Time-based restricted stock and restricted stock units	$	117	$	141	$	172	$	53	1.7
Performance-based restricted stock units	161		123		36		41		1.5
Stock Options					2
Other	8		9		8
Total share-based compensation cost (1)	$	286	$	273	$	218

(1)The income tax benefit realized from share-based compensation was $42 million, $9 million and $17 million, respectively, for the years ended December 31, 2025, 2024 and 2023.

As of December 31, 2025, there were approximately 17 million unissued common shares available for future grants authorized under the Plans.

The following table summarizes the changes in non-vested time-based restricted stock and restricted stock units during the year ended December 31, 2025:


	Number of shares (in thousands)	Weighted-average grant-date fair value
Non-vested as of December 31, 2024	8,456	$	32.94
Granted	1,159	52.02
Vested	(4,083)	32.81
Forfeited	(167)	37.10
Non-vested as of December 31, 2025	5,365	$	37.03

The total fair value of time-based restricted stock and restricted stock units that vested during the years ended December 31, 2025, 2024 and 2023 was approximately $134 million, $208 million and $118 million, respectively.

The following table summarizes the changes in non-vested performance-based restricted stock units during the year ended December 31, 2025:


	Number of shares (in thousands)	Weighted-average grant-date fair value
Non-vested as of December 31, 2024	4,040	$	33.28
Granted	1,507	50.27
Vested	(1,632)	33.70
Performance adjustments	1,003	47.71
Forfeited	(71)	47.16
Non-vested as of December 31, 2025	4,847	$	41.24

The total fair value of performance-based restricted stock units that vested during the years ended December 31, 2025, 2024 and 2023 was approximately $55 million, $47 million and $120 million, respectively.

During the year ended December 31, 2025, 1.7 million options were exercised and 9 thousand options were forfeited and expired with a weighted-average exercise price of $24.35 and $21.35, respectively. As of December 31, 2025, 2.5 million options were outstanding, vested and exercisable, with a weighted-average exercise price of $24.07, weighted average remaining contractual term of 3.4 years and aggregate intrinsic value of $161 million. As of December 31, 2024, 4.2 million options were outstanding, vested and exercisable, with a weighted-average exercise price of $24.18.

The aggregate intrinsic value (market value of stock less option exercise price) represents the total pre-tax intrinsic value, based on the Company’s closing stock price as of December 31, 2025, which would have been received by the option holders had all option holders exercised their “in-the-money” options as of that date.

There were no options granted in 2025, 2024 or 2023. There were no options that vested during the years ended December 31, 2025 and 2024. The total fair value of options that vested during the year ended December 31, 2023 was approximately $6 million.

Proceeds received from the exercise of stock options were $41 million, with a corresponding realized tax benefit of $12 million, for the year ended December 31, 2025. The total intrinsic value of options exercised for the years ended December 31, 2025, 2024 and 2023 was approximately $70 million, $56 million and $29 million, respectively.